The assay is also used to help diagnose mast cell-dependent systemic anaphylaxis, to monitor mast cell cytoreductive therapy, and to assess anaphylactic risk in patients who are sensitive to insect venom. His assay for total tryptase is now used throughout the world to facilitate the diagnosis of systemic mastocytosis (a WHO criterion and FDA approved for this purpose), helping to reveal this disorder in many patients for whom it might otherwise have remained undiagnosed. Noteworthy accomplishments include the discovery, purification, cloning and characterization of human α/β tryptases, creation of immunoassays for tryptases as biomarkers of disorders involving mast cells, development of in vitro conditions for the differentiation of mast cells from progenitors and for culturing tissue-derived mast cells, and the identification of two types of human mast cells. Lawrence Schwartz is an innovative and leading translational research investigator who has made fundamental discoveries about mast cells and basophils, publishing over 350 manuscripts. Schwartz joined the faculty at Harvard in 1979 (Instructor), where he was promoted in 1980 (Assistant Professor), and then moved to Virginia Commonwealth University in 1983, where he is now the Charles and Evelyn Thomas Professor of Medicine, Chair of the Division of Rheumatology Allergy and Immunology, and Program Director of Allergy and Immunology.
Hillblom Foundation, and many of his patients.Lawrence Schwartz received his MD and PhD (Biochemistry) degrees from Washington University in 1976, and then completed an internal medicine residency (Barnes Hospital) and fellowships in allergy and immunology (Brigham & Women’s Hospital), rheumatology (Brigham & Women’s Hospital) and diagnostic laboratory immunology (Virginia Commonwealth University).ĭr. He is grateful for the research support he has received from the NIH, Research Prevent Blindness, the Pritzker Family Fund, the Hellman Foundation, the Larry L. Schwartz’s current efforts are directed at developing novel therapies for age-related macular degeneration and myopic macular degeneration. OCT angiography is playing an increasingly important role in diagnosis and management of age-related macular degeneration, diabetic retinopathy, and other common retinovascular diseases. Scott Fraser and Jeff Fingler, he co-invented OCT angiography, a non-invasive means of imaging the retinal and choroidal vasculature. FDA Approved in 2017, it optimizes vision without spectacles for patients who have had cataract surgery. Robert Grubbs and Julia Kornfield at Caltech, he co-invented the Light Adjustable Lens, an intraocular lens whose power can be adjusted non-invasively using light during the post-operative period. His research focuses on developing new therapies and diagnostics for eye disease. He serves as Director of the Retina Division at the San Francisco VA Medical Center. Schwartz joined the UCSF Department of Ophthalmology in 1990.
0 kommentar(er)
